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0929-6646/Copyright ª 2015, FormosaBackground/purpose: Lipid metabolism is involved in beta amyloid generation, which has been
related with the progression of Alzheimer’s disease (AD). No study has explored the association
between polymorphisms of SAR1 homolog B (SAR1B) and the risk of dementia previously.
Methods: This is a caseecontrol study. A total of 279 AD and 117 vascular dementia (VaD) pa-
tients were recruited from neurology clinics at three teaching hospitals in Taiwan from 2007 to
2010. Controls (n Z 466) were recruited from the elderly health checkup program and volun-
teers in the hospital during the same time interval. Three common (frequency  5%)
haplotype-tagging single nucleotide polymorphisms were selected from the lipid metabolism
gene SAR1B to assess its association with AD and VaD.
Results: Homozygous variants of rs11948613 were associated with a decreased AD risk (CC vs.
TT: adjusted odds ratio Z 0.39, 95% confidence interval Z 0.15e0.98) with a population
attributable risk of 26.7%. This association decreased further in apolipoprotein E ε4 (ApoE
ε4) noncarriers (adjusted odds ratio Z 0.28, 95% confidence interval Z 0.09e0.91). No asso-
ciation was found for VaD. Two common haplotypes (with a cumulative frequency of 95.7%
in controls) were identified for SAR1B, and no association was found for AD or VaD.have no conflicts of interest relevant to this article.
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SAR1B polymorphisms and dementia risk 39Simultaneous screening using rs11948613 and ApoE ε4 significantly improved the sensitivity of
ApoE ε4 alone (from 0.40 to 0.75).
Conclusion: SAR1B polymorphisms were associated with AD risk; results were not significant af-
ter correction for multiple tests. Simultaneous screening using SAR1B rs11948613 and ApoE ε4
status offered a better sensitivity for AD screening.
Copyright ª 2015, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Dementia is characterized by a significant loss in cognitive
function. In Taiwan, the age-adjusted prevalence of all-
cause dementia was 8.04% based on a recent national
survey in 2011e2013.1 In the United States, the incidence
of Alzheimer’s disease (AD), the most common type of
dementia in the elderly, was 1.4% in 1995 and estimated
to reach 4.6% in 2050.2 AD was also the sixth leading cause
of death among the elderly in 2007.3 In addition, de-
mentia contributes to 17% of disability prevalence ac-
cording to the report of World Health Organization in
2004. Therefore, dementia is an important health issue in
the elderly.
The SAR1B gene was first cloned in 20024 and is located
at chromosome 5q31.1. The protein encoded by SAR1B is a
small GTPase, which can be activated by the guanine
nucleotide exchange factor prolactin regulatory element
binding. It is involved in protein transportation from the
endoplasmic reticulum to the Golgi (http://www.ncbi.nlm.
nih.gov/gene/51128). The updated study related to SAR1B
supports the importance of this gene in organs (e.g., liver,
intestine, skeletal muscle, and heart) involved in lipid
transport and/or calcium trafficking in mice.5 The
dysfunction of SAR1B has been related to chylomicron
retention disease,6,7 an autosomal recessive disorder with
severe fat malabsorption, deficiency of fat-soluble vita-
mins, low blood cholesterol levels, and a selective absence
of blood chylomicrons.6,8,9 In addition, metabolic syn-
drome, dyslipidemia, and hypercholesterolemia have been
related to cognitive impairment,10e12 and pathogenesis of
AD13e15 and vascular dementia (VaD).16,17 Therefore, it is
possible that the variations of SAR1B may affect lipid
metabolism or facilitate the formation and aggregation of
beta amyloid (Ab) and tau protein,16,18 which then increase
the risk of dementia.
The SAR1B gene plays a major role in lipid metabolism.
However, previous genome-wide association studies19
failed to identify this gene probably because of (1) the
high false negative rate as a result of insufficient statistical
power and (2) the fact that study populations mainly con-
sisted of white individuals. This study was aimed to explore
the association between SAR1B polymorphisms and the risk
of AD and VaD in a Taiwanese elderly population. Because
apolipoprotein E (ApoE ) ε420e25 and vascular risk factors
(e.g., hypertension, type 2 diabetes, and hyper-
lipidemia)11,13,14,16,26e28 are important risk factors of AD,
stratification analyses were performed to assess how these
factors affect the association described above.Materials and methods
Study population
This was a caseecontrol study. A total of 279 AD and 117
small-vessel VaD patients were recruited from neurology
clinics at three teaching hospitals in northern Taiwan
from 2007 to 2010. Controls (n Z 466) were recruited
from the elderly health checkup program and volunteers
of the hospitals during the same time interval. All study
participants were aged 60 years. Participants were
excluded if they had a history of depression, Parkinson’s
disease, hemorrhagic stroke, cerebral infarction, or brain
tumor, or had dementia subtypes other than AD or small-
vessel VaD. This study was approved by the Institutional
Review Boards of En Chu Kong Hospital, Cardinal Tien
Hospital, and the National Taiwan University Hospital in
Taipei, Taiwan. Written informed consent was obtained
from each study participant. Consent from the legal
guardian/next of kin/caregiver was obtained when the
patient had a serious cognitive impairment. A self-
reported questionnaire was administered to collect in-
formation on demography, dementia status, lifestyle
(e.g., smoking status, alcohol consumption, and exer-
cise), and comorbidity.Dementia evaluation
At each hospital, one neurologist performed clinical ex-
aminations to screen potential dementia cases. Mini-mental
State Examination29 and Clinical Dementia Rating30 were
performed to assess the patients’ cognitive function. The
diagnosis of dementia was evaluated based on the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth
Edition, Text Revision.31 Head magnetic resonance imaging
or computed tomography was taken to exclude participants
with organic lesions. Diagnosis of probable (typical AD
presentation) AD was based on the National Institute of
Neurological and Communicative Disease and Stroke and
the Alzheimer’s Disease and Related Disorders Association
criteria.32 Diagnosis of small-vessel VaD was made accord-
ing to the National Institute of Neurological Disorders and
Stroke-Association Internationale pour la Recherche et
l’Enseignement en Neurosciences criteria.33 Because of the
different etiologies between large- and small-vessel de-
mentia, only VaD patients with small-vessel related stroke
(e.g., lacunar infarction and leukoaraiosis) were included.
The cognitive function of controls was assessed using the
Table 1 Characteristics of the study population.
Variables AD VaD Controls
(n Z 279) (n Z 117) (n Z 466)
Age (y) 79.1  7.0* 79.1  6.5* 72.8  6.0
BMI at age
40s (kg/m2)
22.6  3.1 24.4  3.0* 22.3  2.8
Female 180 (65)* 67 (57) 244 (52)
Education
6 y 140 (51)* 68 (58) 51 (11)
6e12 y 96 (35) 36 (31) 185 (40)
>12 y 40 (14)* 13 (11) 228 (49)
Cigarette smoking 64 (23) 32 (27)* 80 (17)
Alcohol consumption 35 (13) 20 (17) 51 (11)
Hypertension 108 (39)* 79 (68) 247 (53)
Hypercholesterolemia 50 (18)* 27 (23) 140 (30)
Type 2 diabetes 50 (18) 41 (35)* 63 (14)
ApoE ε4 carrier 111 (40)* 26 (22)* 69 (15)
Data are presented as n (%) or mean  SD.
*p < 0.05 for comparing cases (AD or VaD) with controls.
AD Z Alzheimer’s disease; ApoE ε4 Z apolipoprotein E ε4;
BMI Z body mass index; VaD Z vascular dementia.
40 J.-H. Chen et al.Short Portable Mental Status Questionnaire34 to exclude
participants with possible dementia and other mental
disorders.
Single nucleotide polymorphism selection and
genotyping assay
Three common (frequency 5%) single nucleotide poly-
morphisms (SNPs) in SAR1B gene were identified from Han
Chinese in Beijing genotype data of the International HapMap
Project (http://hapmap.ncbi.nlm.nih.gov/). Haploview
(http://www.broadinstitute.org/haploview/haploview) was
used to define haplotype block by applying the modified
Gabriel algorithm.35,36 Three haplotype-tagging SNPs
(htSNPs) (rs7728741, rs2305049, and rs11948613) were
selected by the TagSNP program.37
Blood samples were collected in tubes containing EDTA
for genotyping. After centrifugation, genomic DNA was
extracted from buffy coat by using QuickGene-Mini80 kit
(Fujifilm, Tokyo, Japan) and then stored in a 80C freezer.
Genotypes were determined with TaqMan Genomic Assays
using the ABI 7900 HT fast real-time PCR system (Applied
Biosystems, Foster City, CA, USA). ApoE diplotypes (ε2/ε2,
ε3/ε3, ε2/ε4, ε3/ε4, ε4/ε4) were determined by ApoE 112
(rs429358) and ApoE 158 (rs7412).38 Genotypes of ApoE
SNPs were determined using the assay developed by
Chapman et al.39 Genotyping success rate was > 95% for
each SNPs except rs2305049 (93%). Quality control samples
were replicates of 5% of study participants, and the
concordance rate was 100%.
Statistical analysis
The HardyeWeinberg equilibrium test was performed
among controls for each SNP to examine possible genotyp-
ing error and selection bias. Haplotype frequencies were
estimated using HAPSTAT (http://dlin.web.unc.edu/
software/hapstat/). To control for the confounding effect
of age, the study participants were stratified by an age
interval of 5 years, and cases and controls were compared
within each stratum in the multivariable analysis. We also
adjusted for age in the multivariable regression model in
order to control for residual confounding due to age within
each age stratum. Conditional logistic regression models
were used to estimate adjusted odds ratios (AORs) and 95%
confidence intervals (CIs) in participants carrying either one
or two versus zero copies of minor allele of each SNP. Age,
sex, education, and ApoE ε4 status were adjusted in the
models as they are important covariates. The type I error
rate was controlled by Bonferroni correction40 for the as-
sociation between SAR1B SNPs and dementia risk.
This study further explored how ApoE ε4 status or
vascular risk factors (hypertension, type 2 diabetes, and
hypercholesterolemia) modified the association between
SAR1B polymorphisms and the risk of AD or VaD by using the
likelihood ratio test. Stratified analyses were performed by
these vascular risk factors to assess the association be-
tween SAR1B polymorphisms and the risk of dementia (AD
or VaD). SAS version 9.2 (SAS Institute, Cary, NC, USA) was
used for statistical analyses, and all statistical tests were
two-sided.Simultaneous screening for AD using ApoE ε4 and SAR1B
SNPs was performed. The population attributable risk (PAR)
was estimated with the following equation:
PAR%Z 100 p(odds ratio 1)O [p(odds ratio 1)þ 1],(1)
where p is the prevalence of genotypes associated with AD
among controls.41 Joint PAR was calculated to estimate the
proportion reduction in AD if not carrying variant alleles
using the following equation:
1 e [P(1  PARi)], (2)
where PARi is the individual PAR for each associated SNP
calculated under the full model.42
Results
Characteristics of the study population
This study included 279 AD, 117 VaD cases, and 466 controls
(Table 1). As compared with controls, AD patients were
older (age: 79.1 years vs. 72.8 years), included more fe-
males (65% vs. 52%), had a lower education ( 6 years of
education: 51% vs. 11%), were less likely to have a history of
hypertension (39% vs. 53%) and hypercholesterolemia (18%
vs. 30%), and were more likely to be ApoE ε4 carriers (40%
vs. 15%, Table 1). As compared with controls, VaD patients
were older (79.1 years vs. 72.8 years), had a higher body
mass index at age 40s (24.4 kg/m2 vs. 22.3 kg/m2), and
were more likely to be cigarette smokers (27% vs. 17%), to
have a history of type 2 diabetes (35% vs. 14%), and to be
ApoE ε4 carriers (22% vs. 15%, Table 1).
Table 2 Characteristics of SAR1B htSNPs.
SNP name rs no. Nucleotide change Location HapMap CHB Controls Cases
MAF MAF HWE p MAF HWE p
SNP1 rs7728741 T/C 30-UTR 0.31 0.30 0.56 0.27 0.33
SNP2 rs2305049 G/T Intron 0.31 0.30 0.60 0.28 0.38
SNP3 rs11948613 T/C Intron 0.27 0.26 0.87 0.22 0.45
CHB Z Han Chinese in Beijing, China; HWEZHardyeWeinberg equilibrium; htSNP Z haplotype-tagging single nucleotide poly-
morphisms; MAF Z minor allele frequency; SNP Z single nucleotide polymorphisms; UTR Z untranslated region.
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Three common htSNPs in the SAR1B gene were identified,
and all of them were in HardyeWeinberg equilibrium among
controls (Table 2). Homozygous variants of SAR1B
rs11948613 were associated with decreased AD risk (CC vs.
TT: AOR Z 0.39, 95% CI Z 0.15e0.98; Table 3), which lost
statistical significance after correction for multiple tests.
By contrast, SAR1B polymorphisms were not associated with
the VaD risk (Table 4). Three common htSNPs spanning
SAR1B formed one haplotype block, which was determined
using the modified Gabriel et al algorithm.35,36 Two com-
mon haplotypes with a cumulative frequency of 95.7% in
controls were identified in SAR1B. None of the common
haplotypes was associated with risk for AD (HAP1 TGTA:
AORZ 1.40, 95% CIZ 0.83e2.38; HAP2 CTCA: AORZ 0.86,
95% CI Z 0.64e1.15).
Effect modification by ApoE ε4 status
After stratification by ApoE ε4 status, rs11948613 was
associated with a reduced AD risk among ApoE ε4 non-
carriers (CC vs. TT: AORZ 0.28, 95% CIZ 0.09e0.91; Table
3), which did not reach statistical significance after
correction for multiple tests. ApoE ε4 status did not
significantly modify the association between SAR1B SNPs
and risk of AD (Table 3) or VaD (Table 4).
Effect modification by vascular risk factors
After stratification by hypertension status, the heterozy-
gosity of rs11948613 showed decreased AD risk amongTable 3 Association between SAR1B htSNPs and the risk of Alzh
ApoE ε4 status 0 copies 1 copy
Case/control AOR Case/control AOR (
rs7728741 143/226 1.00 115/198 0.93 (
Noncarriers 98/194 1.00 59/162 0.94 (
Carriers 45/32 1.00 56/34 0.92 (
rs2305049 119/220 1.00 101/194 0.94 (
Noncarriers 78/191 1.00 49/158 1.01 (
Carriers 41/29 1.00 52/34 0.80 (
rs11948613 168/254 1.00 99/181 0.74 (
Noncarriers 111/216 1.00 51/150 0.78 (
Carriers 57/37 1.00 48/30 0.69 (
AOR Z adjusted odds ratios; ApoE ε4 Z apolipoprotein E ε4; CI Z c
polymorphism; NA Z not applicable.
a All models were adjusted for age, sex, and education.nonhypertensive participants (AOR Z 0.52, 95%
CIZ 0.29e0.96), which did not reach statistical significance
after correction for multiple tests. After stratification by
type 2 diabetes or hypercholesterolemia, SAR1B SNPs were
not associated with the risk of AD or VaD (data not shown).
Hypertension, type 2 diabetes, and hypercholesterolemia
did not significantly modify the association between SAR1B
SNPs and risk of AD or VaD (data not shown).
Simultaneous screening and joint PAR of ApoE ε4
and SAR1B rs11948613
ApoE ε4 is a well-known risk factor of late-onset AD.43
However, the sensitivity for screening AD risk was low
when ApoE ε4 and rs11948613 were used separately (0.40
and 0.59, respectively; Table 5). Simultaneous screening
for AD using ApoE ε4 and SAR1B rs11948613 significantly
increased the net sensitivity to 0.75.
Individual PAR is 28.3% and 26.7% for ApoE ε4 and SAR1B
rs11948613, respectively, with a joint PAR of 47.4% (Table 5).
Discussion
No study has explored the association of sequence variants
of SAR1B gene and the risk of dementia (AD and VaD). Ho-
mozygous variants of SAR1B rs11948613 was significantly
associated with a decreased risk of AD (AOR Z 0.39), and
the association decreased further in ApoE ε4 noncarriers
(AOR Z 0.28). However, these associations did not remain
significant after correction for multiple tests. Similarly,
previous genome-wide association studies did not identify
SAR1B as a marker for AD, probably because of the issue ofeimer’s disease by ApoE ε4 status.a
2 copies pinteraction
95% CI) Case/control AOR (95% CI)
0.61e1.43) 17/38 0.57 (0.26e1.27) 0.44
0.57e1.57) 8/35 0.45 (0.17e1.20)
0.41e2.08) 9/3 1.16 (0.25e5.30)
0.61e1.46) 16/38 0.61 (0.27e1.36) 0.12
0.60e1.72) 7/36 0.42 (0.15e1.16)
0.36e1.80) 9/2 1.66 (0.30e9.19)
0.48e1.13) 11/31 0.39 (0.15e0.98) 0.39
0.46e1.29) 5/29 0.28 (0.09e0.91)
0.31e1.51) 6/2 0.77 (0.12e4.99)
onfidence interval; htSNP Z haplotype-tagging single nucleotide
Table 4 Association between SAR1B htSNPs and the risk of vascular dementia by ApoE ε4 status.a
ApoE ε4 status 0 copies 1 copy 2 copies pinteraction
Case/control AOR Case/control AOR (95% CI) Case/control AOR (95% CI)
rs7728741 56/226 1.00 51/198 1.32 (0.75e2.31) 7/38 0.80 (0.26e2.48) 0.89
Noncarriers 40/194 1.00 42/162 1.88 (0.98e3.58) 5/35 0.81 (0.21e3.09)
Carriers 16/32 1.00 8/34 0.38 (0.10e1.45) 2/3 1.11 (0.09e14.2)
rs2305049 56/220 1.00 47/194 1.18 (0.67e2.09) 7/38 0.80 (0.25e2.49) 0.53
Noncarriers 40/191 1.00 38/158 1.63 (0.85e3.14) 5/36 0.73 (0.20e2.73)
Carriers 16/29 1.00 8/34 0.37 (0.10e1.40) 2/2 1.71 (0.12e25.1)
rs11948613 67/254 1.00 42/181 1.12 (0.64e1.97) 7/31 0.87 (0.27e2.80) 0.71
Noncarriers 50/216 1.00 34/150 1.52 (0.79e2.91) 5/29 0.87 (0.22e3.38)
Carriers 17/37 1.00 7/30 0.36 (0.09e1.44) 2/2 1.37 (0.09e20.4)
AORZ adjusted odds ratios; ApoE ε4Z apolipoprotein E ε4; CIZ confidence interval; NAZ not applicable; htSNPsZ haplotype-tagging
single nucleotide polymorphism.
a All models were adjusted for age, sex, and education.
42 J.-H. Chen et al.false negative findings,44 reporting or publication bias, and
the marginal association of SAR1B polymorphisms with AD.
Despite the marginal association, we found that the
addition of rs11948613 for simultaneous screening with
ApoE ε4 can significantly improve the sensitivity compared
with using ApoE ε4 alone (from 0.4 to 0.75). Previous
studies showed that ApoE ε4 has low sensitivity (about 0.40)
when it was used alone for screening AD.45,46 This may have
a beneficial impact on public health, especially when
screening larger populations for AD risk at an early stage.
Because these are germline polymorphisms, AD risk can be
predicted at any point of a person’s life, and thus they
become stable and reliable biomarkers. In simultaneous
screening, “positive” indicates positive results in any one or
more of the tests, whereas “negative” indicates negative
results in all of the tests. This leads to a gain in net sensi-
tivity but a loss in net specificity.47 Both SAR1B and ApoE
genes are involved in lipid metabolism and the regulation of
high-density lipoprotein, total cholesterol, low-density li-
poprotein, and triglyceride. Dyslipidemia increases the
accumulation of Ab and is thus related to increased risk of
AD13 and VaD.48 Fewer noncarriers had dyslipidemia, as
compared to ApoE ε4 carriers, which may explain the
interplay between SAR1B and ApoE ε4, although it did not
reach statistical significance. In addition, no protective
effect was found for SAR1B SNPs among ApoE ε4 carriers,
probably because of the strong deleterious effect of ApoETable 5 Simultaneous screening and joint PAR of ApoE ε4
and SAR1B rs11948613 for Alzheimer’s disease.
Sensitivitya Specificityb PAR (%)
ApoE ε4 0.40 0.85 28.3
rs11948613 0.59 0.45 26.7
Net sensitivity 0.75 NA NA
Net specificity NA 0.38 NA
Joint PAR (%) NA NA 47.4
ApoE ε4 Z apolipoprotein E ε4; NA Z not applicable;
PAR Z population attributable risk.
a Net sensitivity Z sensitivity1 þ sensitivity2 e
sensitivity1  sensitivity2.
b Net specificity Z specificity1  specificity2.ε4, which cannot be counteracted by the protective effect
of variant SAR1B.
In this study, ApoE ε4 status and vascular risk factors
(e.g., hypertension, type 2 diabetes, and hypercholester-
olemia) did not modify the association between SAR1B
polymorphisms and dementia. Hypertension, hyperlipid-
emia, and type 2 diabetes may affect the pathogenesis of
dementia.49e52 The nonsignificant findings may be attrib-
utable to medications for treating these diseases.53e55 In
this study, among hypertensive patients who took the
medication, 30% were AD patients and 70% were controls.
Among nonhypertensive patients and hypertensive patients
without medication, 44% were AD patients and 56% were
controls. Among hypercholesterolemia patients who took
the medication, 23% were AD patients and 77% were con-
trols. Among nonhypercholesterolemia patients and hy-
percholesterolemia patients without medication, 40% were
AD patients and 60% were controls. Based on the above
results, hypertension and hypercholesterolemia under
medication may have a protective effect against AD.
This study has several strengths. First, no study has
explored the association of sequence variants of SAR1B and
the risk of AD or VaD. Second, all AD or VaD patients were
evaluated by neurologists supplementary with brain imag-
ing to minimize the misclassification of dementia subtypes.
Third, simultaneous screening using ApoE ε4 and SAR1B
polymorphism significantly improved the sensitivity of ApoE
ε4 for AD screening.
This study also has several limitations. First, the infor-
mation on vascular risk factors (e.g., hypertension, hyper-
cholesterolemia, and type 2 diabetes) was obtained from a
self-report questionnaire instead of medical charts. How-
ever, by a random sampling of 5% of all participants, a high
concordance rate (> 95%) was found between self-reported
and medical record-confirmed vascular diseases. In addi-
tion, previous studies showed that the participants’
awareness of these major health issues was high if their
disease had been diagnosed by physicians.56e58 Therefore,
information bias was not a concern. Second, the sample
size of VaD is relatively small and may therefore over-
estimate OR/PAR owing to insufficient statistical power to
assess the association between SAR1B genetic poly-
morphisms and the risk of VaD.
SAR1B polymorphisms and dementia risk 43SAR1B polymorphisms may protect against AD via the
facilitation of lipid metabolism. This study found that
SAR1B rs11948613 was associated with a risk of AD; how-
ever, the results were not significant after correction for
multiple tests. In addition, simultaneous screening using
ApoE ε4 and the SAR1B rs11948613 may offer a potential
screening tool for predicting AD risk at an early stage.
Future large studies will be needed to confirm these
findings.
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